• 1
    Pizzo PA,Poplack DG. Principles and Practice of Pediatric Oncology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
  • 2
    Bleyer WA. The U.S. pediatric cancer clinical trials programmes: international implications and the way forward. Eur J Cancer. 1997; 33: 14391447.
  • 3
    Bleyer WA,Tejeda H,Murphy SB, et al. National cancer clinical trials: children have equal access; adolescents do not. J Adolesc Health. 1997; 21: 366373.
  • 4
    Grovas A,Fremgen A,Rauck A, et al. The National Cancer Data Base report on patterns of childhood cancers in the United States. Cancer. 1997; 80: 23212332.
  • 5
    Ablett S,Doz F,Morland B,Vassal G, New Agents Group of the United Kingdom Children's Cancer Study Group (UKCCSG), Pharmacology Group of the French Society of Paediatric Oncology (SFOP). European collaboration in trials of new agents for children with cancer. Eur J Cancer. 2004; 40: 18861892.
  • 6
    Schneider DT,Calaminus G,Koch S, et al. Epidemiologic analysis of 1,442 children and adolescents registered in the German germ cell tumor protocols. Pediatr Blood Cancer. 2004; 42: 169175.
  • 7
    Ablett S,Pinkerton CR, United Kingdom Children's Cancer Study Group (UKCCSG). Recruiting children into cancer trials—role of the United Kingdom Children's Cancer Study Group (UKCCSG). Br J Cancer. 2003; 88: 16611665.
  • 8
    McTiernan A. Issues surrounding the participation of adolescents with cancer in clinical trials in the UK. Eur J Cancer Care (Engl). 2003; 12: 233239.
  • 9
    Bleyer A,Budd T,Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006; 107: 16451655.
  • 10
    Bleyer A. Older adolescents with cancer in North America deficits in outcome and research. Pediatr Clin North Am. 2002; 49: 10271042.
  • 11
    Bleyer A. The adolescent and young adult gap in cancer care and outcome. Curr Probl Pediatr Adolesc Health Care. 2005; 35: 182217.
  • 12
    Adolescent and Young Adult Oncology Progress Review Group. Closing the gap: research and care imperatives for adolescents and young adults with cancer. Bethesda, MD: National Cancer Institute; 2006;06-6067.
  • 13
    Bleyer A,O'Leary M,Barr R,Ries L. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975–2000. NIH Pub. No. 06-5767:1-14-173-190. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2006.
  • 14
    Bleyer A,Ries L. United States cancer incidence, mortality and survival: young adults are lagging further behind. Proc Am Soc Clin Oncol. 2002; 21: 389a.
  • 15
    Bleyer A,Smith M, Coordinators. Enhancing accrual of adolescent and young adult cancer patients on clinical trials. NCI Workshop. Bethesda, MD, June 17, 1999.
  • 16
    Bleyer WA. Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol. 2002; 38: 110.
  • 17
    Meadows AT. Pediatric cancer survivors: past history and future challenges. Curr Probl Cancer. 2003; 27: 112126.
  • 18
    Bleyer A,Viny A,Barr R. Cancer in 15- to 29-year-olds by primary site. Oncologist. 2006; 11: 590601.
  • 19
    Albritton KH. Sarcomas in adolescents and young adults. Hematol Oncol Clin North Am. 2005; 19: 527546, vii.
  • 20
    Anderson BD,Smith MA,Reaman GH,Kodish ED. Re: views of American oncologists about the purposes of clinical trials. J Natl Cancer Inst 2003; 95: 630631, author reply 631.
  • 21
    Cortes J,Giles F,O'Brien S, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha. Blood. 2003; 102: 8386.
  • 22
    Bleyer A,Montello M,Budd T,Saxman S. National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer. 2005; 103: 18911897.
  • 23
    Meyers PA,Heller G,Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993; 11: 449453.
  • 24
    Paulussen M,Ahrens S,Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies.European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol. 1998; 9: 275281.
  • 25
    Punyko JA,Mertens AC,Baker KS,Ness KK,Robison LL,Gurney JG. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer. 2005; 103: 14751483.
  • 26
    Joshi D,Anderson JR,Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the Children's Oncology Group. Pediatr Blood Cancer. 2004; 42: 6473.
  • 27
    Parham DM,Ellison DA. Rhabdomyosarcomas in adults and children: an update. Arch Pathol Lab Med. 2006; 130: 14541465.
  • 28
    Ferrari A,Dileo P,Casanova M, et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer. 2003; 98: 571580.
  • 29
    Pratt CB,Maurer HM,Gieser P, et al. Treatment of unresectable or metastatic pediatric soft tissue sarcomas with surgery, irradiation, and chemotherapy: a Pediatric Oncology Group study. Med Pediatr Oncol. 1998; 30: 201209.
  • 30
    Pratt CB,Pappo AS,Gieser P, et al. Role of adjuvant chemotherapy in the treatment of surgically resected pediatric nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group study. J Clin Oncol. 1999; 17: 1219.
  • 31
    Pappo AS,Devidas M,Jenkins J, et al. Phase II trial of neoadjuvant vincristine, ifosfamide, and doxorubicin with granulocyte colony-stimulating factor support in children and adolescents with advanced-stage nonrhabdomyosarcomatous soft tissue sarcomas: a Pediatric Oncology Group study. J Clin Oncol. 2005; 23: 40314038.
  • 32
    Van Glabbeke M,van Oosterom AT,Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens—a European organization for research and treatment of cancer soft tissue and bone sarcoma group study. J Clin Oncol. 1999; 17: 150157.
  • 33
    Kildahl-Andersen A,Erke MG,Sagstuen H,Bremnes RM. Patients with non-seminoma germ cell tumours treated in a minor oncology department: the importance of multi-institutional protocols and research collaboration. Acta Oncol. 2005; 44: 537544.
  • 34
    Einhorn LH,Donohue J. Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer. Ann Intern Med. 1977; 87: 293298.
  • 35
    Motzer RJ,Nichols CJ,Margolin KA, et al. Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol. 2007; 25: 247256.
  • 36
    Schmoll HJ,Souchon R,Krege S, et al. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol. 2004; 15: 13771399.
  • 37
    Vaughn DJ,Stadtmauer EA. Poor-prognosis germ cell tumors: we have not yet crossed the finish line. J Clin Oncol. 2007; 25: 239240.
  • 38
    Nichols CR,Catalano PJ,Crawford ED,Vogelzang NJ,Einhorn LH,Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B study. J Clin Oncol. 1998; 16: 12871293.
  • 39
    Nichols CR,Williams SD,Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991; 9: 11631172.
  • 40
    Kaye SB,Mead GM,Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a randomized medical research Council/European organization for research and treatment of cancer study. J Clin Oncol. 1998; 16: 692701.
  • 41
    Marina N,London WB,Frazier AL, et al. Prognostic factors in children with extragonadal malignant germ cell tumors: a pediatric intergroup study. J Clin Oncol. 2006; 24: 25442548.
  • 42
    Cushing B,Giller R,Cullen JW, et al. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a Pediatric Intergroup Study—Pediatric Oncology Group 9049 and Children's Cancer Group 8882. J Clin Oncol. 2004; 22: 26912700.
  • 43
    Rauck AM,Fremgen AM,Hutchison CL,Grovas AC,Ruyman FB,Menck HR. Adolescent cancers in the United States: a National Cancer Data Base (NCDB) report. J Pediatr Hematol Oncol. 1999; 21: 310.
  • 44
    Zebrack B,Bleyer A,Albritton K,Medearis S,Tang J. Assessing the health care needs of adolescent and young adult cancer patients and survivors. Cancer. 2006; 107: 29152923.
  • 45
    Klein-Geltink J,Shaw AK,Morrison HI,Barr RD,Greenberg ML. Use of paediatric versus adult oncology treatment centres by adolescents 15–19 years old: the Canadian childhood cancer surveillance and control program. Eur J Cancer. 2005; 41: 404410.
  • 46
    Collins SR,Schoen C,Kriss JL,Doty MM,Mahato B. Rite of passage? Why young adults become uninsured and how new policies can help. Issue Brief (Commonwealth Fund). 2006; 20: 114.
  • 47
    DeNavas-Walt C,Proctor BD,Lee CH. Income, poverty, and health insurance coverage in the United States: 2004. U.S. Census Bureau, Current Population Reports, 2005. P60-229:16-21. Washington, DC: U.S. Census Bureau; 2005.
  • 48
    Paulussen M,Ahrens S,Juergens HF. Cure rates in Ewing tumor patients aged older than 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. Proc Am Soc Clin Oncol. 2003; 22: 816a.
  • 49
    Whelan J,Seddon B,Perisoglou M. Management of osteosarcoma. Curr Treat Options Oncol. 2006; 7: 444455.